C-Reactive protein in end-stage renal disease: Are there reasons to measure it?

Blood Purification

Volumn 23, Issue 1, 2005, Pages 72-78

  Stenvinkel, Peter ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular disease; Inflammation; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL GRAFT; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CORONARY ARTERY ATHEROSCLEROSIS; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM INJURY; HEART DEATH; HUMAN; KIDNEY FAILURE; LIFESPAN; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE ACTIVATION; MEDICAL ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK FACTOR; SMOOTH MUSCLE FIBER;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 11444265154     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082014     Document Type: Article

References (65)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998;32(suppl 5):S112-S119.
2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant of uremia: Oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
4. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
5. Pasceri V, Yeh ETH: A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-2126.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1615-1617.
8. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
9. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
10. Ridker PM, Wilson PWF, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-2825.
11. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000;321:199-204.
12. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
13. Glynn RJ, Cook NR: C-reactive protein and coronary heart disease. N Engl J Med 2004;351:295-298.
14. Libby P, Willerson JT, Braunwald E: C-reactive protein and coronary heart disease. N Engl J Med 2004;351:295-296.
15. Ridker PM, Koenig W, Fuster V: C-reactive protein and coronary heart disease. N Engl J Med 2004;351:296-297.
16. Stenvinkel P: Interactions between inflammation, oxidative stress and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003;13:144-148.
17. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al: Interleukin-10, IL-6 and TNF-α: Important factors in the altered cytokine network of end-stage renal disease - The good, the bad and the ugly. Kidney Int 2004, in press.
18. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang JW: Modulation of C-reactive proteinmediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
19. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
20. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-2067.
21. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
22. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, et al: C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886-1891.
23. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
24. Hattori Y, Matsumura M, Kasai K: Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58:186-195.
25. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
26. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, et al: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-1392.
27. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, Suriyaphol P, et al: Possible protective role for C-reactive protein in atherogenesis: Complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004;109:1870-1876.
28. Sternik L, Samee S, Schaff HV, Zehr KJ, Lerman LO, Holmes DR, et al: C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol 2003;22:1865-1868.
29. van den Berg CW, Taylor KE, Lang D: C-Reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004;24:1-4.
30. Verma S, Wang CH, Weisel RD, Badiwala MV, Li SH, Fedak PW, et al: Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: Reversal with rosiglitazone. J Mol Cell Cardiol 2003;35:417-419.
31. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, et al: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002;62:1791-1798.
32. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, et al: Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42:44-52.
33. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella MC, Stenvinkel P: Inflammation, malnutrition and atherosclerosis in end-stage renal disease: A global perspective. Blood Purif 2002;20:454-458.
34. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
35. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
36. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999;14:1956-1960.
37. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1998;18:387-394.
38. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M: C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002;62:1417-1422.
39. Wang A, Woo J, Wai Kei C, Wang M, Man-Sei M, Lui S-F, et al: Is a single time-point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003;14:1871-1879.
40. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, et al: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002;40:1230-1239.
41. Korevaar JC, van Manen JG, Dekker FD, de Waart DR, Boeschoten EW, Krediet RT: Effect of an increase in CRP level during a hemodialysis session on mortality. J Am Soc Nephrol 2004;15:2916-2922.
42. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al: Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001;12:814-821.
43. Kim SB, Min WK, Lee SK, Park JS, Hong CD, Yang WS: Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2002;39:342-346.
44. Pifer TB, McCullogh KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, et al: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-2245.
45. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF, et al: White blood cells as a novel predictor in haemodialysis patients. Nephrol Dial Transplant 2003;18:1167-1173.
46. Bologa RM, Levine DM, Parker TS, Cheigh JS, Seur D, Stenzel KH, et al: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
47. Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P: Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688.
48. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160.
49. Stenvinkel P, Heimbürger O, Wang T, Lindholm B, Bergström J, Elinder CG: High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999;34:1083-1088.
50. 50a Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, et al: Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003;254:132-139.
51. 50b Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, NECOSAD Study Group: Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004;15:2916-2922.
52. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ: Septicemia in the United States dialysis population 1991-1999. J Am Soc Nephrol 2004;15:1038-1045.
53. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
54. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-1218.
55. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, et al: Fate of injected interleukin 1 in rats: Sequestration and degradation in the kidney. Cytokine 1990;2:416-422.
56. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al: The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-544.
57. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-2194.
58. 57a Ayus JC, Sheikh-Hamad D: Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998;9:1314-1321.
59. 57b Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Benitez P, Villaverde M, Perez-Garcia R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004;15:2494-2501.
60. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, et al: Inflammatory signals associated with hemodialysis. Kidney Int 2002;62:1408-1416.
61. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al: Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO study. J Am Soc Nephrol 2003;14:1863-1870.
62. Blake GJ, Ridker PM, Kuntz KM: Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 2003;15:485-494.
63. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules and all cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modelling. J Am Soc Nephrol 2004, in press.
64. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003;25:1486-1491.
65. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al: Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003;92:522-528.